Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target

LOS ANGELES, March 5 Vista Partners announced today thatit has updated coverage and has issued a $3.52 price target on InovioBiomedical Corporation (Amex: INO). "Inovio has compelling pre-clinical andclinical data regarding the ability of their technology to significantlyenhance the potency of DNA vaccines, with positive interim human results fromthree independent clinical studies. The company's technology is furthervalidated from license agreements with two of the world's big five vaccinecompanies, Merck and Wyeth, plus multiple other partnerships andcollaborations," said Ross Silver, Director of Research for Vista Partners.For more information and to download the report, please visit the VistaPartners website at http://www.vistap.com.

About Vista Partners:

Vista Partners provides independent, equity research to institutional andindividual investors, with a focus on publicly traded small capitalizationcompanies. With offices in Los Angeles and San Francisco, Vista Partners isone of the fastest growing independently owned equity research firms. VistaPartners professional staff has backgrounds in finance, corporatecommunications and investment banking. More information is available athttp://www.vistap.com.

About Inovio Biomedical Corporation:

Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-basedimmunotherapies. Inovio is a leader in developing human applications ofelectroporation using brief, controlled electrical pulses to increase cellularuptake of a useful biopharmaceutical. Interim human data has shown thatInovio's DNA delivery technology can significantly increase gene expressionand immune responses from DNA vaccines. Immunotherapy partners include Merck,Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army,National Cancer Institute, and International Aids Vaccine Initiative. Inovio'stechnology is protected by an extensive patent portfolio covering in vivoelectroporation. More information is available at http://www.inovio.com.Contact: Vista Partners LLC Ross Silver (415) 738-6229 [email protected] http://www.vistap.com

SOURCE Vista Partners

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...